Polyganics Receives Funding for Clinical Development of Liver and Pancreas Sealant Patch
Polyganics reports that its easy-to-use device is optimized to effectively adhere to and seal off the surgically treated tissue throughout the critical healing period after hepato-pancreato-biliary (HPB) surgery.
Polyganics recently announced that it has received €1.2 million (approximately $1.3 million) in funding from the European Fund for Regional Development (EFRO) through the Northern Netherlands Alliance (SNN) and the city and province of Groningen to support clinical validation of its liver and pancreas sealant patch. The grant will support a safety and performance study that is scheduled to take place later this year in multiple clinical centers across Europe.
Polyganics reports that its easy-to-use device is made of the company’s synthetic and safe bio-resorbable polymers. It is optimized to effectively adhere to and seal off the surgically treated tissue throughout the critical healing period after hepato-pancreato-biliary (HPB) surgery. The patch functions both as a sealant (withstanding the impact of aggressive bile and pancreatic fluids) and as a hemostat (controlling mild-to-moderate bleeding). It is being developed in close association with the surgical department of the University Medical Center Hamburg-Eppendorf (UKE), Germany, and with MercachemSyncom, a contract research organization located in Groningen.